Trial Profile
Uncontrolled phase I dose escalation, safety and pharmacokinetic study of SSR244738 administered as a one-hour intravenous infusion weekly in patients with refractory solid tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Feb 2007
Price :
$35
*
At a glance
- Drugs SSR 244738 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 22 Feb 2007 New trial record.